THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) Shareholders approve all proposed resolutions EINDHOVEN, The Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that that all proposed res ...

Market Overview - U.S. stocks showed a mostly positive trend, with the Dow Jones index increasing by 0.28% to 42,986.17, NASDAQ rising by 0.09% to 19,731.97, and S&P 500 gaining 0.06% to 6,042.25 [1] - Information technology shares experienced a notable increase of 0.6%, while materials stocks fell by 0.6% [1] Company Performance - SailPoint, Inc. saw its shares surge by 18% to $23.22 after reporting better-than-expected first-quarter adjusted EPS and raising its FY26 guidance above estimates [6] - Helius Medical Technologies, Inc. experienced an 85% increase in shares to $1.56 following the announcement of an authorized claim for payment for its PoNS Device from Aetna Healthcare [6] - Ouster, Inc. shares rose by 24% to $19.94 after the Department of Defense approved its OS1 digital lidar for use in unmanned aerial systems [6] - LeddarTech Holdings Inc. shares dropped by 40% to $0.2226 due to significant layoffs and potential bankruptcy [6] - Chewy, Inc. shares fell by 12% to $40.44 after reporting first-quarter results and issuing FY25 sales guidance below estimates [6] - Draganfly Inc. shares decreased by 41% to $2.1950 after announcing a public offering priced at $2.50 per unit [6] Investment Opportunities - Boxabl is positioning itself as a major disruptor in the housing market with interest for over 190,000 homes and a focus on high-efficiency production inspired by assembly line methods [6] - Boxabl's homes are priced at $60,000, and the company is raising $1 billion to scale production, offering investors a chance to participate in its growth [6][8]

Cerus (CERS) FY 2025 Conference June 11, 2025 08:40 AM ET Speaker0 Well, good morning, everyone. My name is Obi Greenman. I am the CEO of Cirrus. I'm here with my colleague, Kevin Green, who's the CFO of Cirrus in the back room there. I just want to thank Goldman Sachs for the opportunity to present our company Cirrus today. Before I start, I will want to acknowledge the forward looking statements that I'll be making today and encourage you all to read the SEC Form 10 Q and 10 ks risk factors just to be awa ...

Core Viewpoint - BrainsWay Ltd. announced preliminary results from a multicenter, randomized controlled trial indicating that the accelerated Deep TMS protocol for treating major depressive disorder is comparable in efficacy to the standard protocol while requiring fewer clinic visits [1][2]. Group 1: Study Overview - The trial involved 104 adult patients diagnosed with depression across eight sites, making it the largest randomized, controlled, blinded, multicenter trial of an accelerated Deep TMS protocol [2]. - Patients were divided into two groups: one receiving standard Deep TMS treatment and the other receiving the accelerated protocol [2]. Group 2: Treatment Protocol - The accelerated group underwent five sessions per day over six treatment days, followed by eight sessions over the next four weeks, significantly reducing the treatment burden [3]. - The primary endpoint was the change in depressive symptoms measured by the HDRS-21 scale, with secondary endpoints including response and remission rates [3]. Group 3: Key Findings - The accelerated Deep TMS group showed comparable efficacy with HDRS depression scores reduced by 18.9 points, while the standard group saw a reduction of 19.9 points [7]. - Response and remission rates were 87.8% and 78.0% for the accelerated group, compared to 87.5% and 87.5% for the standard group [7]. - Sessions for the accelerated protocol lasted less than 10 minutes, compared to 20 minutes for standard sessions [7]. - The median time to remission was 21 days for the accelerated group versus 28 days for the standard group [7]. - The accelerated protocol was well-tolerated with no serious adverse events reported, and side effects were mild [7]. Group 4: Company Commitment - BrainsWay emphasizes that innovation in mental health care involves not only new technology but also improving care delivery methods [5]. - The company is dedicated to expanding access to Deep TMS and advancing the field through scientific research [5]. - The accelerated protocol is investigational and not yet FDA-cleared, with preliminary results subject to further analysis and peer review [5]. Group 5: Company Background - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS platform technology [8]. - The company has obtained three FDA-cleared indications for major depressive disorder, obsessive-compulsive disorder, and smoking addiction [8]. - Founded in 2003, BrainsWay operates in the United States and Israel, focusing on increasing global awareness and access to Deep TMS [8].

EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and independence in people with spinal cord injury and other movement disabilities, today announces that it will host a webcast to discuss its Q1 2025 business update and year-to-date highlights. The webcast will be held on June 17, 2025, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver. ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 在 皮肤疾病 的诊断和管理方面，充分利用 人工智能 （AI） 的潜力迫在眉睫。尽管深度学习已展现出卓越的性能，常常能与皮肤科医生相媲美甚至超越，但目前 用于皮肤科的 AI 模型仍局限于孤立的任务 （例如从皮肤镜图像中诊断皮肤癌） 。这些模型难以整合各种数据类型和成像模式，从而降低了其在不同实际临床环 境中的实用性。 皮肤科与内科一样，本质上十分复杂，涵盖了从常见皮肤病到危及生命的恶性肿瘤等广泛的病症，因此需要一种全面的、以患者为中心的方法，将各种临床工作 流程整合起来。 2025 年 6 月 6 日，澳大利亚莫纳什大学 戈宗元 团队 （博士生 燕思远 为第一作者） 在 Nature Medicine 期刊发表了题为 ： A multimodal vision foundation model for clinical dermatology 的研究论文。 该研究开发了一种 用于临床皮肤科的多模态视觉基础模型—— PanDerm ，其在 包括皮肤癌筛查、风险分层、常见和罕见皮肤疾病的鉴别诊断、病变分割、纵向 监测以及转移预测和预后在内的 28 种的基准测试中达到了最先进的 ...

GE HealthCare Technologies (GEHC) FY Conference June 10, 2025 10:00 AM ET Speaker0 Good morning, everybody. Just make a quick reminder that presentations are not open to to members of the press. So that, I'd like to welcome GE Healthcare here, Jay Sicarro, Chief Financial Officer and Carolyn Borders, Head of Investor Relations. As I've mentioned in all of these, happy to keep this interactive. And if you do want to ask a question, we'll just get a mic over to you so those participating via webcast can hear ...

Core Insights - NeuroStar, a Silver Sponsor at the 13th Annual Clinical TMS Society (CTMSS) Meeting, is committed to clinical innovation and excellence in mental health care [1][2] - The company will present two significant poster presentations based on the TrakStar data set, which is the largest real-world outcomes database in TMS [2][3] - NeuroStar aims to optimize TMS efficacy and expand its use into new populations and protocols, reinforcing its leadership in the psychiatric community [3] Company Updates - NeuroStar will present a retrospective analysis comparing clinical outcomes between its proprietary Figure-8 coil and Brainsway's H-coil in treating depression [2] - The company is evaluating personalized qEEG-informed protocols for TMS therapy, demonstrating operational feasibility with the NeuroStar TMS System [4] - NeuroStar has delivered over 7.4 million treatments and operates Greenbrook TMS centers across the U.S. for treating Major Depressive Disorder (MDD) and other mental health disorders [6] Event Participation - The CTMSS Meeting will take place from June 11-14 in San Diego, CA, where NeuroStar will also participate in the PULSES Course for TMS providers [2] - Presentations will include data on elderly adults (age 70 and older) with MDD treated with TMS, and a retrospective analysis from 200 Greenbrook centers [7]

DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4 – 6 in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe. Key Presentati ...

Core Insights - BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, showcasing its Deep TMS technology at the Clinical TMS Society's 2025 Annual Meeting [1][4] - The company will present preliminary results from a multicenter randomized non-inferiority trial comparing its standard Deep TMS protocol to a novel accelerated protocol [2] - BrainsWay is the first and only TMS company to obtain three FDA-cleared indications, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [4] Company Overview - BrainsWay was founded in 2003 and operates in the United States and Israel, focusing on improving health through its proprietary Deep TMS platform technology [4] - The company is dedicated to advancing neuroscience and increasing global awareness and access to Deep TMS treatments [4] Clinical Research Highlights - The latest Deep TMS research will be featured in poster presentations at the conference, emphasizing the technology's advantages over first-generation TMS systems [3] - A Phase IV Registry Study demonstrated that 49% of patients successfully quit smoking after 15 treatment sessions using the Deep TMS H4 Coil [5] - A post-marketing surveillance study involving over 1,200 adolescent patients showed the efficacy and safety of Deep TMS for adolescent depression [5]